Kornimate/medical-research-clean huggingface dataset:
toripalimab adjuvant therapy in subjects with resected esophageal squamous cell carcinoma who achieved pathological complete response (pcr)

Conditions: Esophageal Squamous Cell Carcinoma Stage II; Esophageal Squamous Cell Carcinoma Stage III

Summary: the goal of this clinical trial is to assess the 1-year dfs rate of toripalimab adjuvant therapy in participants with resected esophageal squamous cell carcinoma (escc) who achieved pcr. the main questions it aims to answer are: * the toripalimab adjuvant therapy could impove the 1-year dfs rate in participants with rescted escc who achieved pcr? * is this treatment regimen safe? researchers will compare toripalimab adjuvant therapy to clinical observation to see if toripalimab could improve the 1-year dfs rate. participants will receive toripalimab 240 mg iv once every 3 weeks for one year or clinical observation.


Eligibility criteria:
inclusion criteria: * stage ii or iii esophageal cancer with histologically confirmed predominant squamous cell carcinoma at initial diagnosis; * subjects must complete preoperative neoadjuvant therapy (unlimited treatment regimen) before being assigned to treatment and then undergo surgery; * subjects must undergo complete resection (r0), be surgically determined to be disease-free and have a negative margin on the resected specimen, defined as no viable tumor within 1 mm of the proximal, distal, or surrounding resection boundary; * subjects must have no residual pathology, the primary tumor is pcr, and the pathology report of the resected lymph nodes is ypn0; * ecog performance status of 0 or 1; * the laboratory test meet the following requirements: bone marrow function: neutrophils ≥ 1.5×10(9)/l, platelets ≥ 100×10(9)/l, hemoglobin ≥ 90 g/l liver function：total bilirubin ≤ 1.5 x uln；ast and alt ≤ 3 x uln renal function：cr ≤ 1.5 x uln，ccr ≥ 50 ml/min. exclusion criteria: * subjects with stage m1 resectable disease； * received treatments for resected esophageal cancer (e.g., immunotherapy , chemotherapy, targeted therapy, radiotherapy, or biologic therapy); * known to be allergic, highly sensitive or intolerable to research-related drugs or excipient * in the past 5 years, there were other malignant tumors, melanoma skin cancer or ervical carcinoma in situ were excepted.
study of support groups for african-american breast cancer survivors

Conditions: Breast Cancer; Cancer Survivor

Summary: rationale: a study that evaluates successful los angeles-based, peer-led african american breast cancer survivor support groups may help in developing a guide on how to organize and maintain breast cancer support groups. purpose: this clinical trial is studying support groups for african-american breast cancer survivors.

objectives: * characterize five established los angeles (la)-based, peer-led african american breast cancer survivor (aabcs) support groups by identifying and evaluating the successful elements of structure and process that distinguish these groups: the purpose and goals; theories and techniques that are utilized; the structure of the group and implementation of specific goals; the cultural aspects that are incorporated to enhance the efficacy; and similarities and differences among these aabcs support groups. * develop a preliminary "culturally informed breast cancer support group guide" on how to organize and maintain support groups, modeled on the "best model" experiences of the five established la-based support groups for aabcs. * conduct three needs-assessment focus groups and 5 key informant interviews in the inland empire to evaluate the psychosocial needs and resources of aabcs in that region. outline: at least 10 support group leaders (2 from each support group) undergo semi-structured interviews to elicit information about the needs of breast cancer survivors in their community and the cultural modes of support that are given. eight to twelve african american breast cancer survivors (aabcs) participate in 5 focus group discussions and complete a questionnaire about their breast cancer and experience with support groups for qualitative and quantitative analysis. at least 5 inland empire community leaders undergo semi-structured interviews to elicit information about the needs of breast cancer survivors in their community. eight to twelve aabcs from the inland empire participate in 3 focus group discussions and complete a questionnaire about their breast cancer and experience with support groups for qualitative and quantitative analysis.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * african american breast cancer survivor (aabcs) meeting 1 of the following criteria: * a member of 1 of the 5 support groups listed below * live in the inland empire region of california * a cancer support group leader or facilitator of 1 of the 5 established support groups in los angeles: * women of essence (woe) * women of color (woc) * support sisters african american breast cancer support groups * sisters * celebrate life * a community leader knowledgeable about breast cancer support services in the inland empire region patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer cancer survivor
proteasome inhibitor ps-341 relapsed or refractory b cell lymphomas previously treated with chemotherapy

Conditions: Lymphoma, B-Cell

Summary: purpose of phase ii study for b-cell lymphoma using ps341: evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory b-cell non-hodgkin's lymphoma.

patients were stratified, based on preclinical data, into arm a (mantle-cell lymphoma) or arm b (other b-cell lymphomas) without limitation in number of prior therapies. bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles.

Eligibility criteria:
inclusion: * relapsed or refractory b cell lymphoma. * zubrod status \</= 3. * measurable disease. * no anti-cancer treatment within past 3 weeks. * anc \>= 1500/ul, plt \>/= 50,000, bilirubin \ /1000, plt\>/30000 will be eligible if due to massive splenomegaly and/or bm involvement. * hiv negative. * no active cns lymphoma. * no serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma. * not eligible for treatment of a higher priority. patients may be entered before bmt. * no pregnancy \& age bearing females must be practicing adequate contraception. * age \> 16. exclusion: * patients with platelets \<30x10(9)/l within 14 days before enrollment. * patients with anc\<1.0 x10(9)/l within 14 days before enrollment. * patients with peripheral neuropathy \>/= grade 3 within 14 days before enrollment.

Keywords: cancer relapsed refractory b cell lymphoma proteasome inhibitor ps-341
adebrelimab plus chemotherapy as neoadjuvant therapy in resectable nsclc harboring driver gene mutations

Conditions: Non Small Cell Lung Cancer

Summary: this is a prospective, single-arm study to investigate the efficacy and safety of adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations


Eligibility criteria:
inclusion criteria: * male or female aged ≥18 years. * eastern cooperative oncology group (ecog) performance status of 0-1. * resectable non-small cell lung cancer harboring driver gene mutations. * at least one measurable disease based on response evaluation criteria in solid tumors 1.1. * have adequate organ function. * female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication；females should not be breastfeeding；female subjects of childbearing potential as well as males sexually active with women of childbearing potential must be willing to use an adequate method of contraception. * voluntarily comply with the treatment protocol. exclusion criteria: * previously treated with any anti-tumor therapy; * subject with known autoimmune disease * subject with known history of testing positive for human immunodeficiency virus (hiv) or known to have acquired immunodeficiency syndrome (aids), subject has known active hepatitis b or c. * presence of third space effusion that cannot be controlled by drainage or other means (e.g., excessive pleural fluid and ascites). * subject with severe liver and kidney dysfunction. * subjects who need to use corticosteroids (\>10 mg/day prednisone or equivalent dose of similar drugs) or other immunosuppressive therapy for systematic treatment within 14 days before the first administration of the study * subject with previous malignancies within 5 years, except for cured in situ cancer. * subject with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-induced pneumonia and severe damage to lung function. * subject with uncontrolled hypertension. * prior organ transplantation including allogenic stem-cell transplantation. * known hypersensitivity to the study drug or any of its excipients. * other situations that the investigator considers unsuitable for the enrollment.
percutaneous cryoablation versus partial nephrectomy for t1b renal tumor

Conditions: Renal Tumor

Summary: the aim of our study is to assess the long-term oncological and functional outcomes of cryoablation for t1b renal tumors, as well as such important parameters as the patient's quality of life after treatment, and to compare the results with those after partial nephrectomy.


Eligibility criteria:
inclusion criteria: •ct-confirmed renal mass \> 4 to 7 cm (t1b) exclusion criteria: * multiple renal tumors; * recurrence of renal tumor; * intolerance to iodine-containing contrast agents; * pregnancy; * patients with bosniak 4 cysts * presence of other oncological diseases; * impossibility of organ-preserving treatment due to the proximity of the tumor to the vessels or the calyx-pelvic system * absence of malignant pathology based on prior biopsy.

Keywords: cryoablation renal cancer partial nephrectomy
optimizing diagnostics of arrhythmia events in children using intelligent telemetric solutions

Conditions: Arrhythmia; Children

Summary: the purpose of this study is to assess efficacy of prolonged full disclosure electrocardiogram (ecg) monitoring and signal analysis using advanced telemetric technology to diagnose arrhythmia in comparison with standard diagnostic procedure.

irregular and/or rapid beating of the heart called heart palpitations can occur in individuals without heart disease and the reasons for their palpitations are unknown. together with heart palpitations silent arrhythmia may be present that could lead to serious complications (eg. stroke). in others, palpitations result from heart rhythm disturbances, sometimes life threatening. standard diagnostic methods such as 24 hours holter electrocardiogram (ecg) monitoring or event holter do not guarantee early diagnosis of the arrhythmia. prolonged heart rhythm recording and analysis using an automatic full disclosure telemetric device can increase probability of arrhythmia diagnosis and early administration of applicable treatment. study patients will be diagnosed using standard holter ecg monitoring, event holter or 30 days telemetric ecg monitoring. efficacy of telemetric monitoring in diagnosis of cardiac arrhythmia will be assessed in comparison with the standard holter monitoring and event holter

Eligibility criteria:
inclusion criteria: * history of symptoms that can be potentially caused by cardiac arrhythmia occuring at least 4 times a year * ability to operate the telemetric device at home * informed consent undersigned by the parents * informed consent undersigned by the child if over 16 years of age exclusion criteria: * previously recorded tachycardia evidence * wolff parkinson white syndrome * inability to operate the telemetric device at home * inability to comply with the study protocol

Keywords: arrhythmia children
homecare integral support program for ipf patients

Conditions: Idiopathic Pulmonary Fibrosis

Summary: homecare patient support program especially designed for covering ipf patient needs, implemented for 12 months, for improving quality of life

the proposed comprehensive ipf home care programme consists of: 1) improving patient's quality of life (autonomy, activity, emotional well-being and symptoms), 2) reducing the number and severity of side effects associated with the anti-fibrotic drug, 3) reducing the number of hospitalisations attributable to the disease, and 4) providing a rapid response to any problem associated with the disease (after diagnosis or progression) that may cause distress or require early action.

Eligibility criteria:
inclusion criteria: * ipf patients with fvc \> 50% and dlco \> 30%, in whom pharmacological treatment with nintedanib was started at least one month before the start of the programme. exclusion criteria: * hospitalised patients or those who have been hospitalised in the previous month, due to any kind of respiratory exacerbation or due to any other respiratory cause. * patients who are under home care controls (pades) as this implies an advanced stage of the disease (forced vital capacity \[fvc\] less than 50% and the diffusion capacity of the lungs for carbon monoxide \[dlco\] less than 30%) or, patients thathave a lack of autonomy due to comorbidities or respiratory failure * patients diagnosed in incipient phase who have neither symptoms nor limitation in their usual activities. * patients who have suffered any other life-threatening disease in the last 2 years, such as cancer or uncontrolled ischaemic heart disease. * inability to understand the information given to the patient, relating to the legal aspects of the informed consent.

Keywords: homecare patient support
novel mechanisms and predictors of vegf receptor inhibitor- or immune checkpoint inhibitor-associated hypertension and cardiovascular disease

Conditions: Renal Cell Carcinoma; Hypertension; Melanoma; Cancer

Summary: the purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (vegf) inhibitor, immune checkpoint-inhibitor (ici), and combination treatment on blood pressure and blood vessel function.


Eligibility criteria:
inclusion criteria: * male or female, age 40 - 75 years old * diagnosis of cancer * receiving vegf inhibitor, ici, or combination (vegf inhibitor + ici or combination ici) treatment, or not receiving any treatment. * normal blood pressure or blood pressure treated to \< 140/90 mm hg with ≤2 antihypertensive medications exclusion criteria: * presence of peripheral artery disease * history of a heart attack within 1 year * history of a stroke within 1 year * diabetes * life expectancy \< 3 months * women who are pregnant * women who are nursing
study comparing etanercept plus methotrexate to either etanercept or methotrexate alone in rheumatoid arthritis.

Conditions: Active Rheumatoid Arthritis

Summary: to compare the therapeutic and radiographic effects and safety between etanercept, methotrexate, and the etanercept/methotrexate combination in patients with rheumatoid arthritis.

etanercept is an injection administered under the skin twice weekly. methotrexate is a tablet to be taken once weekly. patients will not know which treatment they are on. patients will need to meet the study criteria to be enrolled in the study and sign an informed consent.

Eligibility criteria:
inclusion: - generally healthy of at least 18 years of age with active rheumatoid arthritis. exclusion: - a history or presence of clinically important medical disease.

Keywords: arthritis rheumatoid safety
palliative and oncology care intervention: symptom coach

Conditions: Cancer of Head and Neck

Summary: the investigators propose to conduct the first pilot trial of a collaborative palliative and oncology care intervention for hnc patients receiving crt to assess the feasibility and acceptability of the intervention. the intervention will incorporate weekly palliative care visits into standard oncology care targeting coping, mood, and symptom management.


Eligibility criteria:
inclusion criteria: 1. adult patients (≥18 years) with a diagnosis of hnc for which they are undergoing crt 2. receiving all oncology care at fox chase cancer center (fccc) 3. able to speak and read in english or with assistance from an interpreter exclusion criteria: 1. patients with prior history of hnc for which they underwent crt 2. patients with uncontrolled psychiatric disorders (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease which the treating clinician believes prohibits informed consent or participation in the study 3. patients enrolled on other supportive care intervention trials
effects of blood flow restriction training in rotator cuff related shoulder pain

Conditions: Subacromial Pain Syndrome

Summary: blood flow restriction training is widespread in sport performance areas, where it has proven to be beneficial in strength and hypertrophy development. however, there are only few studies related to its effects on subjects with pathology, and currently, there is no recent clinical trial evaluating its effects on patients with rcrsp. we are aiming to define the potential benefits, acute and short-term effects of adding blood flow restriction to a low-load exercise training for patients with rcrsp.


Eligibility criteria:
inclusion criteria: * pain around the antero-lateral (deltoid area) region of the proximal shoulder during active movements in abduction and/or external rotation. * 3/5 positive impingement tests: neer, hawkins-kennedy, empty can, painful arc, and resisted external rotation or abduction. * pain at rest less than 3cm in a visual analogue scale (vas). exclusion criteria: * previous shoulder surgery. * being treated with physical therapy or pharmacogical therapy for shoulder pain. * external rotation range of motion less than 45º or 50% compared to the contralateral side. * suspected shoulder instability (previous dislocation/subluxation, sulcus sign, anterior drawer test, anterior/posterior aprehension test, relocation test). * suspected cervical radiculopathy (distraction, spurling, ulnt1, squeeze test, ipsilateral rotation less than 60º) * presence of neck pain. * suspected rotator cuff tears (drop arm test, external rotation lag sign, diagnostic imaging). * contraindications to blood flow restriction therapy.
the time of positive conversion of interferon-γ releasing assay after tuberculosis exposure

Conditions: Tuberculosis

Summary: the aim is to evaluate the time of positive conversion after exposure to smear positive pulmonary tuberculosis (tb) in a platoon of korean military, a closed communal setting.

in a platoon where tb outbreak occurred, we performed low dose chest ct (ldct), quantiferon-tb gold in tube (qft) and two-step (0, 4weeks) tst for outbreak investigation. we perform qft at 0, 2, 4, 8 and 12 weeks after initial investigation for soldiers with negative qft results, and soldiers with positive qft and normal ldct took isoniazid and rifampin for 3 months as treatment of latent tb.

Eligibility criteria:
inclusion criteria: * all soldiers who assigned to the military platoon where a tuberculosis outbreak occurred exclusion criteria: * soldiers who could not complete study or refused the study protocol

Keywords: tuberculosis quantiferon outbreak conversion
incidence of postthoracotomy pain following general anesthesia: a comparison between tiva and inhalation anesthesia

Conditions: Lung Cancer; Neoplasms, Lung

Summary: the purpose of this study is to evaluate the incidence of postthoracotomy pain between total intravenous anesthesia (tiva)and inhalation anesthesia after lung surgery.

thoracotomy is one of the most painful surgical incisions. it has been shown that 5-80% of patients still suffer from thoracic pain 2-3 months after surgery and the international association for the study of pain (iasp) defines postthoracotomy pain syndrome (ptts)as pain that recurs or persists at least 2 months after surgical procedure. previous reports have shown that the incidence of ptts varies according to preoperative pain, pain intensity, sex, and types of procedure. however, little is known about the effect of the type of anesthesia to postthoracotomy pain.

Eligibility criteria:
inclusion criteria: * patients undergo elective thoracotomy of lung surgery exclusion criteria: * emergency operation age under 18 years patients with unstable hemodynamics
study to assess safety and effectiveness of branebrutinib treatment in participants with active systemic lupus erythematosus or primary sjögren's syndrome, or branebrutinib treatment followed by open-label abatacept treatment in study participants with active rheumatoid arthritis

Conditions: Autoimmune Disorder; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Primary Sjögren's Syndrome

Summary: the purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic lupus erythematosus (sle) or primary sjögren's syndrome (pss), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: sub-study for systemic lupus erythematosus (sle) * active sle as defined by the systemic lupus erythematosus international collaborating clinics (slicc) classification * diagnosed with sle more than 24 weeks before screening visit sub-study for primary sjögren's syndrome (pss) * moderate to severe pss, meeting acr-eular classification criteria sub-study for active rheumatoid arthritis (ra) * moderate to severe adult-onset ra * acr global functional status class i to iii women and men must agree to follow instructions for methods of contraception. exclusion criteria: sub-study for sle * certain other autoimmune diseases and overlap syndromes sub-study for pss * certain other immune-mediated diseases, active fibromyalgia, or other medical conditions sub-study for ra * diagnosis with juvenile arthritis or idiopathic arthritis before age 16 for all sub-studies: * history of any significant drug allergy * active infection, significant concurrent medical condition, or clinically significant abnormalities other protocol defined inclusion/exclusion criteria could apply